Antares Pharma — Investor Presentation (January 2021)
28 slides from Antares Pharma's investor presentation, Jan 11, 2021
Slide 1: January 2021 Investor Presentation
NASDAQ: ATRS | January 2021 Investor Presentation EX 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate
Slide 3: Investment Highlights
Leverage pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas Investment Highlights Diversified revenue provides opportunities for continued growth Commercial XYOSTED®, OTREXUP® and NOCDURNA® Commercial Generic EpiPen®, Generi
Slide 4: Long-Term Growth Strategy
Long-Term Growth Strategy Expand Partnership Opportunities A leader in self-administered injection technology Support life-cycle management solutions Disciplined Capital Allocation Corporate development In-licensing opportunities Enhance Proprietary Portfolio Support research and development Leverag
Slide 5: Rapidly Growing and Diversified Revenue Mix
Rapidly Growing and Diversified Revenue Mix Proprietary Products Partner Products Development Royalty
Slide 6: Proprietary Products
Proprietary Products (desmopressin acetate) sublingual tablet
Slide 7: Patient-Centric Innovation Drives Strategy
Patient-Centric Innovation Drives Strategy Targeting two therapeutic areas with significant market opportunities UROLOGY & ENDOCRINOLOGY Focus on patient populations with high unmet needs Target addressable physician audiences for efficient commercialization Identify and develop innovative, differen
Slide 8: XYOSTED (testosterone enanthate) for injection
Innovative self-delivery of testosterone (T) replacement therapy for at-home use T levels maintained for as long as the patient remains on therapy* Convenient, once-a-week dosing Virtually painless subcutaneous injection ~72% of all commercial lives covered ~32,000 patients prescribed since launch X
Slide 9: Testosterone Market
Testosterone Market Once Weekly Painless Efficacious Steady PK No Risk of Transfer IQVIA Data
Slide 10: XYOSTED Quarterly TRx Growth
XYOSTED® Quarterly TRx Growth ~210,000 XYOSTED TRx’s (as of January 1, 2021) Written by ~7,500 different physicians (as of January 1, 2021) 3Q 2020 TRx’s increased ~15% sequentially 43,997 38,274 27,702 19,183 11,001 4,003 IQVIA Calculated Packaged Units 33,164
Slide 11: XYOSTED Broad Utilization Across Specialties
XYOSTED® Broad Utilization Across Specialties 3Q 2020 IQVIA Data
Slide 12: Focused Sales Effort to Optimize Current Portfolio
Branded TRT and RA/MTX market Cover ~90% of the TRT prescribers in the top 3 deciles Every territory has 120-150 top decile prescriber ~95% of OTREXUP® volume is covered Highly tenured sales team with ~15-20 years of experience 79 SARs, 10 RSMs, NSD (90 FTE) Flexible ‘virtual’ team (6 PSR’s) patient
Slide 13: In-Licensed: NOCDURNA (desmopressin acetate)
FDA-approved, on market vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times a night to void First and only sublingual tablet that targets the kidneys Short-acting desmopressin is considered standard-of-care but underutilized du
Slide 14: NOCDURNA Works Quickly
NOCDURNA® Works Quickly References: 1. NOCDURNA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Aditya S et al. Int J Appl Basic Med Res. 2012;2(2):77-83 Please see Prescribing Information including important safety information and boxed warning. A sublingual tablet that dissolves
Slide 15: Antares Assets in Development
ATRS-1901 Urology Asset Antares Assets in Development ATRS-1902: Endocrinology Asset Completed Pre-IND meeting with FDA Expected IND filing in 1H 2021 ATRS-1901: Urology Asset Completed Pre-IND meeting with FDA Expected IND filing in 2H 2021
Slide 16: Partner Business
a antares Partner Business teva amar ‘wonsta = GZ
Slide 17: Pharmaceutical Technology Partner
Deep Device Knowledge Drug/Device Combination Product Partner Extensive Regulatory Expertise and Success Tailored Durable Asset Development PHARMACEUTICAL TECHNOLOGY PARTNER Partner Business Revenue (in millions)
Slide 18: Commercial Experience: Teva's Generic EpiPen
Commercial Experience Teva’s Generic EpiPen FDA-approved as therapeutically equivalent to Mylan’s EpiPen® and fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on in-market sales EpiPen, Sr. limited commercial l
Slide 19: Generic EpiPen Quarterly TRx Prescription Trends
Generic EpiPen® Quarterly TRx Prescription Trends Bloomberg/Symphony Health Solutions
Slide 20: Generic Forteo (teriparatide)
Generic Forteo® (teriparatide) Teva awaiting FDA approval for their ANDA for generic Forteo® Expect six-month exclusivity Fully substitutable at pharmacy Teva launched in 11 European countries and Israel and Canada Forteo® 2019 revenue $646 million in U.S. $759 million in ROW by Lilly ATRS will supp
Slide 21: Global Development Agreement with Idorsia for selatogrel
Global Development Agreement with Idorsia Pharmaceuticals for selatogrel, a New Chemical Entity, with the QuickShot auto injector selatogrel Selatogrel is a fast acting and highly selective P2Y12 receptor antagonist intended for the treatment of suspected Acute Myocardial Infarction (AMI) Phase 2 da
Slide 22: Myocardial Infarction Market Opportunity
~750,000 occurrences of new or recurrent MI1 annually 550,000 have a first MI + 200,000 have a recurrent MI Myocardial Infarction Market Opportunity 1. Mozaffarian D et al. Circulation 2016 Onset of action of all oral P2Y12 inhibitors may be delayed by >6 hours in the setting of acute myocardial inf
Slide 23: Diversified Product Portfolio
Diversified Product Portfolio Testosterone Methotrexate Desmopressin Acetate Sumatriptan Epinephrine Hydroxyprogesterone Teriparatide Teriparatide Exenatide P2Y12 Receptor Antagonist Undisclosed Undisclosed Undisclosed XYOSTED® OXTREXUP® NOCDURNA® SUMATRIPTAN EPINEPHRINE MAKENA® TERIPARATIDE (ROW) T
Slide 24: Revenue Growth and 2020/2021 Projections
Revenue Growth and 2020/2021 Projections. Net Income / (Loss) = = ra Ls Riera Gross Margin OPEX as % of Revenue rhonda peng i ici
Slide 25: Income Statement Summary
Income Statement Summary Pins {in millions, except Margin Total Operating Expenses Net income / (Loss) Eamings/ (Loss) Per Share. 40.0 343 17% 105.5, 86.0 23% 176 22 62% 1% sas $0.03 49.6 58% 542 $(0.08) 283% 3
Slide 26: Antares Pharma: Value Proposition
Antares Pharma: Value Proposition Diverse portfolio of commercialized products Multiple growth drivers Continued XYOSTED® prescription growth Continued generic EpiPen® prescription growth Relaunch of NOCDURNA® Potential FDA approval and U.S. launch of Teva’s generic teriparatide Pfizer development p
Slide 27: Value Enhancing Catalysts in the Near-Term
Value Enhancing Catalysts in the Near-Term 2020 revenue guidance of $145-150M In-license NOCDURNA® to leverage commercial organization Teva’s launch of generic teriparatide in 11 countries in EU, Canada and Israel Successful Pre-IND meeting with FDA for proprietary urology asset Successful Pre-IND m
Slide 28: Thank You!
Thank You! BP antares making medicines better”
Antares Pharma — Investor Presentation (January 2021) on 6ix